BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

CHEMICON International, Inc. (SERO) Expands Its Exclusive Agreement For Patented Compounds And Methods For Embryonic Stem - ES - Cell Research


10/19/2005 5:13:12 PM

ATLANTA & MELBOURNE, Australia--(BUSINESS WIRE)--April 5, 2005--Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, CA, has expanded its exclusive worldwide agreement with Amrad Corporation Ltd (ASX: AML, Melbourne, Australia) and The Walter and Eliza Hall Institute of Medical Research (WEHI, Melbourne, Australia). The new agreement provides Chemicon additional rights to further develop its proprietary embryonic stem cell products, Leukemia Inhibitory Factor (LIF) and ESGRO(R) into additional kits and combination products. This new agreement provides an important expansion of the initial license agreement covering LIF patent rights signed by Chemicon, Amrad and WEHI in 1999 to include additional fields of use in non-therapeutic fields. The new license affirms Chemicon's exclusive rights to develop, manufacture, sublicense and distribute LIF and LIF based products in the research market worldwide and expands the company's ability to develop, manufacture and commercialize diagnostic products. The new exclusive license also gives Chemicon access to patents and applications that cover LIF production and uses in various biotechnology applications. Through this agreement, Chemicon expands its rights to access Amrad's LIF and embryonic stem cell intellectual property portfolio, which now totals 45 granted and 7 pending patents for both LIF and ESGRO(R) applications. Amrad has retained all other rights under the LIF patents and patent applications for therapeutic applications and associated research activities.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->